Deng Guanjun, Zhang Siwei, Peng Xinghua, Ma Gongcheng, Liu Luxuan, Tan Yuyu, Gong Ping, Tang Ben Zhong, Cai Lintao, Zhang Pengfei
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055, P.R. China.
Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong 999077, P.R. China.
Chem Biomed Imaging. 2024 Apr 12;2(10):683-688. doi: 10.1021/cbmi.4c00011. eCollection 2024 Oct 28.
Methylene blue (MB) is an FDA (Food and Drug Administration)-approved contrast agent with donor-acceptor (D-A) structure integrated with carbonyl-containing nitrogen-heterocycles. MB can be converted into MBH (protonated MB) by protonation, which not only induces the fluorescence emission red-shifted from the first near-infrared window (NIR-I, 650-950 nm) to the second near-infrared window (NIR-II, 1000-1700 nm) but also achieves ACQ-to-AIE conversion. MB has been successfully demonstrated in hyperacidemia imaging with an extremely low pH value (<1).
亚甲蓝（MB）是一种经美国食品药品监督管理局（FDA）批准的造影剂，其供体-受体（D-A）结构与含羰基的氮杂环整合。MB可通过质子化转化为MBH（质子化亚甲蓝），这不仅会使荧光发射从第一近红外窗口（NIR-I，650-950nm）红移至第二近红外窗口（NIR-II，1000-1700nm），还能实现聚集猝灭到聚集诱导发光的转变。MB已在极低pH值（<1）的高酸血症成像中得到成功验证。
